A prospective study to compare the diagnostic accuracy of 99mTc-CNDG SPECT/CT and contrast-enhanced CT in staging of non-small cell lung cancer.

IF 2.7 3区 医学 Q3 ONCOLOGY Journal of Cancer Research and Clinical Oncology Pub Date : 2024-09-26 DOI:10.1007/s00432-024-05953-6
Qinfen Wang, Zhensheng Deng, Chuangang Lu, Lijun Chen, Jiangjun Qin, Ping Wang
{"title":"A prospective study to compare the diagnostic accuracy of <sup>99m</sup>Tc-CNDG SPECT/CT and contrast-enhanced CT in staging of non-small cell lung cancer.","authors":"Qinfen Wang, Zhensheng Deng, Chuangang Lu, Lijun Chen, Jiangjun Qin, Ping Wang","doi":"10.1007/s00432-024-05953-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the value of <sup>99m</sup>Tc-isonitrile deoxyglucosamine (CNDG) SPECT/CT in the staging and resectability diagnosis of non-small cell lung cancer (NSCLC) compared with contrast-enhanced CT (CECT).</p><p><strong>Methods: </strong>This research was approved by the hospital ethics review committee. Sixty-three patients with NSCLC received <sup>99m</sup>Tc-CNDG SPECT/CT, CECT and initial TNM staging before treatment. Thirty-three patients who underwent radical surgery underwent postoperative pathological TNM staging as the reference standard. Another thirty patients underwent radiochemotherapy; among them, the reference standard of 7 patients of N staging and 5 patients of M staging was based on biopsy pathology, and the diagnosis of the remaining lesions was confirmed by at least one different image or clinical imaging follow-up for more than 3 months. The McNemar test and receiver operating characteristic (ROC) curve analysis were used to compare the diagnostic accuracy of staging and resectability of <sup>99m</sup>Tc-CNDG SPECT/CT and CECT in NSCLC, respectively.</p><p><strong>Results: </strong>For all patients and surgical patients, the accuracies of <sup>99m</sup>Tc-CNDG SPECT/CT in diagnosing the T stage and N stage were higher than those of CECT (all patients: 90.5%, 88.9% vs. 79.4%, 60.3%; surgical patients: 81.8%, 78.8% vs. 60.6%, 51.5%), and the differences were statistically significant (all patients: T stage, P = 0.016; N stage, P = 0.000; surgical patients: T stage, P = 0.016; N stage, P = 0.004). For all patients, the accuracy of <sup>99m</sup>Tc-CNDG SPECT/CT in diagnosing the M stage was higher than that of CECT (96.8% vs. 90.5%), but the difference was not statistically significant (P = 0.289). ROC curve analysis showed that the accuracy of <sup>99m</sup>Tc-CNDG SPECT/CT in diagnosing the potential resectability of NSCLC was significantly better than that of CECT (P = 0.046).</p><p><strong>Conclusion: </strong>This preliminary clinical study shows that <sup>99m</sup>Tc-CNDG SPECT/CT is of great value for accurate clinical staging of NSCLC compared with CECT and can significantly improve the accuracy of resectability diagnosis.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 9","pages":"430"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427526/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-024-05953-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To explore the value of 99mTc-isonitrile deoxyglucosamine (CNDG) SPECT/CT in the staging and resectability diagnosis of non-small cell lung cancer (NSCLC) compared with contrast-enhanced CT (CECT).

Methods: This research was approved by the hospital ethics review committee. Sixty-three patients with NSCLC received 99mTc-CNDG SPECT/CT, CECT and initial TNM staging before treatment. Thirty-three patients who underwent radical surgery underwent postoperative pathological TNM staging as the reference standard. Another thirty patients underwent radiochemotherapy; among them, the reference standard of 7 patients of N staging and 5 patients of M staging was based on biopsy pathology, and the diagnosis of the remaining lesions was confirmed by at least one different image or clinical imaging follow-up for more than 3 months. The McNemar test and receiver operating characteristic (ROC) curve analysis were used to compare the diagnostic accuracy of staging and resectability of 99mTc-CNDG SPECT/CT and CECT in NSCLC, respectively.

Results: For all patients and surgical patients, the accuracies of 99mTc-CNDG SPECT/CT in diagnosing the T stage and N stage were higher than those of CECT (all patients: 90.5%, 88.9% vs. 79.4%, 60.3%; surgical patients: 81.8%, 78.8% vs. 60.6%, 51.5%), and the differences were statistically significant (all patients: T stage, P = 0.016; N stage, P = 0.000; surgical patients: T stage, P = 0.016; N stage, P = 0.004). For all patients, the accuracy of 99mTc-CNDG SPECT/CT in diagnosing the M stage was higher than that of CECT (96.8% vs. 90.5%), but the difference was not statistically significant (P = 0.289). ROC curve analysis showed that the accuracy of 99mTc-CNDG SPECT/CT in diagnosing the potential resectability of NSCLC was significantly better than that of CECT (P = 0.046).

Conclusion: This preliminary clinical study shows that 99mTc-CNDG SPECT/CT is of great value for accurate clinical staging of NSCLC compared with CECT and can significantly improve the accuracy of resectability diagnosis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
比较 99mTc-CNDG SPECT/CT 和对比增强 CT 对非小细胞肺癌分期诊断准确性的前瞻性研究。
目的探讨99m锝-异腈脱氧葡糖胺(CNDG)SPECT/CT与造影剂增强CT(CECT)相比在非小细胞肺癌(NSCLC)分期和可切除性诊断中的价值:本研究获得了医院伦理审查委员会的批准。63名NSCLC患者在治疗前接受了99m锝-CNDG SPECT/CT、CECT和TNM初步分期。接受根治性手术的 33 例患者以术后病理 TNM 分期作为参考标准。其中7例N分期患者和5例M分期患者的参考标准为活检病理,其余病灶的诊断则由至少一张不同的图像或超过3个月的临床影像学随访证实。采用McNemar检验和接收者操作特征曲线(ROC)分析分别比较99m锝-CNDG SPECT/CT和CECT对NSCLC分期和可切除性的诊断准确性:结果:对于所有患者和手术患者,99m锝-CNDG SPECT/CT 诊断 T 期和 N 期的准确率均高于 CECT(所有患者:90.5%;手术患者:88.9%):90.5%、88.9% vs. 79.4%、60.3%;手术患者:81.8%、78.8% vs. 60.6%、51.5%),差异有统计学意义(所有患者:T 期,P = 0.01;手术患者:N 期,P = 0.01):所有患者:T 期,P = 0.016;N 期,P = 0.000;手术患者:T 期,P = 0.016;N 期,P = 0.000:T期,P = 0.016;N期,P = 0.004)。在所有患者中,99m锝-CNDG SPECT/CT 诊断 M 期的准确率高于 CECT(96.8% 对 90.5%),但差异无统计学意义(P = 0.289)。ROC曲线分析显示,99m锝-CNDG SPECT/CT诊断NSCLC潜在可切除性的准确性明显优于CECT(P = 0.046):这项初步临床研究表明,与 CECT 相比,99m锝-CNDG SPECT/CT 对 NSCLC 的临床准确分期具有重要价值,并能显著提高可切除性诊断的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.00
自引率
2.80%
发文量
577
审稿时长
2 months
期刊介绍: The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses. The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
期刊最新文献
Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centres. Zinc oxide nanoparticles mitigate the malignant progression of ovarian cancer by mediating autophagy-dependent ferroptosis. TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis. USP33 is an integrin α6 deubiquitinase and promotes esophageal squamous cell carcinoma cell migration and metastasis. Dosimetric evaluation of different cylinder diameters in three-dimensional vaginal brachytherapy for early-stage endometrial cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1